These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 36871006)

  • 1. Potential clinical biomarkers and perspectives in diabetic cardiomyopathy.
    Deng J; Yan F; Tian J; Qiao A; Yan D
    Diabetol Metab Syndr; 2023 Mar; 15(1):35. PubMed ID: 36871006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Circulating Biomarkers in Diabetic Cardiomyopathy.
    Ianoș RD; Cozma A; Lucaciu RL; Hangan AC; Negrean V; Mercea DC; Ciulei G; Pop C; Procopciuc LM
    Biomedicines; 2024 Sep; 12(9):. PubMed ID: 39335666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of miR-223 attenuates the NLRP3 inflammasome activation, fibrosis, and apoptosis in diabetic cardiomyopathy.
    Xu D; Zhang X; Chen X; Yang S; Chen H
    Life Sci; 2020 Sep; 256():117980. PubMed ID: 32561396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy.
    Zhang L; Ai C; Bai M; Niu J; Zhang Z
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological Functions and Clinical Prospects of Extracellular Non-Coding RNAs in Diabetic Cardiomyopathy: an Updated Review.
    Yin Z; Chen C
    J Cardiovasc Transl Res; 2022 Jun; 15(3):469-476. PubMed ID: 35175553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of ROS/Chloride Efflux-Mediated NLRP3 Inflammasome Activation Contributes to Alleviation of Diabetic Cardiomyopathy in Rats after Sleeve Gastrectomy.
    Li S; Dong S; Shi B; Xu Q; Li L; Wang S; Zhang W; Zhong M; Zhu J; Cheng Y; Zhang G; Hu S
    Oxid Med Cell Longev; 2022; 2022():4608914. PubMed ID: 35498125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Serum Biomarkers in Early Detection of Diabetic Cardiomyopathy in the West Virginian Population.
    Shaver A; Nichols A; Thompson E; Mallick A; Payne K; Jones C; Manne ND; Sundaram S; Shapiro JI; Sodhi K
    Int J Med Sci; 2016; 13(3):161-8. PubMed ID: 26941576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyroptosis-Related Inflammasome Pathway: A New Therapeutic Target for Diabetic Cardiomyopathy.
    Cai Z; Yuan S; Luan X; Feng J; Deng L; Zuo Y; Li J
    Front Pharmacol; 2022; 13():842313. PubMed ID: 35355717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potential biomarkers for diabetic cardiomyopathy using LC-MS-based metabolomics.
    Xiong RQ; Li YP; Lin LP; Yao JY
    Endocr Connect; 2024 Mar; 13(3):. PubMed ID: 38180052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic cardiomyopathy--fact or fiction?
    Maisch B; Alter P; Pankuweit S
    Herz; 2011 Mar; 36(2):102-15. PubMed ID: 21424347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NLRP3 Inflammasome in Diabetic Cardiomyopathy and Exercise Intervention.
    Sun Y; Ding S
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy.
    Luo B; Huang F; Liu Y; Liang Y; Wei Z; Ke H; Zeng Z; Huang W; He Y
    Front Physiol; 2017; 8():519. PubMed ID: 28790925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
    Luo B; Li B; Wang W; Liu X; Xia Y; Zhang C; Zhang M; Zhang Y; An F
    PLoS One; 2014; 9(8):e104771. PubMed ID: 25136835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclovirobuxine D Ameliorates Experimental Diabetic Cardiomyopathy by Inhibiting Cardiomyocyte Pyroptosis
    Gao G; Fu L; Xu Y; Tao L; Guo T; Fang G; Zhang G; Wang S; Qin T; Luo P; Shen X
    Front Pharmacol; 2022; 13():906548. PubMed ID: 35865939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Krill Oil Inhibits NLRP3 Inflammasome Activation in the Prevention of the Pathological Injuries of Diabetic Cardiomyopathy.
    Sun X; Sun X; Meng H; Wu J; Guo X; Du L; Wu H
    Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of novel biomarkers in diabetic cardiomyopathy.
    Kumric M; Ticinovic Kurir T; Borovac JA; Bozic J
    World J Diabetes; 2021 Jun; 12(6):685-705. PubMed ID: 34168722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H3 Relaxin Protects Against Myocardial Injury in Experimental Diabetic Cardiomyopathy by Inhibiting Myocardial Apoptosis, Fibrosis and Inflammation.
    Zhang X; Pan L; Yang K; Fu Y; Liu Y; Chi J; Zhang X; Hong S; Ma X; Yin X
    Cell Physiol Biochem; 2017; 43(4):1311-1324. PubMed ID: 28992627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions.
    Huo JL; Feng Q; Pan S; Fu WJ; Liu Z; Liu Z
    Cell Death Discov; 2023 Jul; 9(1):256. PubMed ID: 37479697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of myocardial lipidomics profiling in a rat model of diabetic cardiomyopathy using UPLC/Q-TOF/MS analysis.
    Dong S; Zhang R; Liang Y; Shi J; Li J; Shang F; Mao X; Sun J
    Diabetol Metab Syndr; 2017; 9():56. PubMed ID: 28736579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating circRNA as biomarkers for dilated cardiomyopathy etiology.
    Costa MC; Calderon-Dominguez M; Mangas A; Campuzano O; Sarquella-Brugada G; Ramos M; Quezada-Feijoo M; Pinilla JMG; Robles-Mezcua A; Del Aguila Pacheco-Cruz G; Belmonte T; Enguita FJ; Toro R
    J Mol Med (Berl); 2021 Dec; 99(12):1711-1725. PubMed ID: 34498126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.